PT - JOURNAL ARTICLE AU - Cassar, Mark Philip AU - Tunnicliffe, Elizabeth M. AU - Petousi, Nayia AU - Lewandowski, Adam J. AU - Xie, Cheng AU - Mahmod, Masliza AU - Abd Samat, Azlan Helmy AU - Evans, Rachael A. AU - Brightling, Christopher E. AU - Ho, Ling-Pei AU - Piechnik, Stefan K. AU - Talbot, Nick P. AU - Holdsworth, David AU - Ferreira, Vanessa M. AU - Neubauer, Stefan AU - Raman, Betty TI - Symptom Persistence Despite Improvement in Cardiopulmonary Health – Insights from longitudinal CMR, CPET and lung function testing post-COVID-19 AID - 10.1101/2021.08.03.21260940 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.03.21260940 4099 - http://medrxiv.org/content/early/2021/08/05/2021.08.03.21260940.short 4100 - http://medrxiv.org/content/early/2021/08/05/2021.08.03.21260940.full AB - Background The longitudinal trajectories of cardiopulmonary abnormalities and symptoms following infection with coronavirus disease (COVID-19) are unclear. We sought to describe their natural history in previously hospitalised patients, compare this with controls, and assess the relationship between symptoms and cardiopulmonary impairment at 6 months post-COVID-19.Methods Fifty-eight patients and thirty matched controls underwent symptom-questionnaires, cardiac and lung magnetic resonance imaging (CMR), cardiopulmonary exercise test (CPET), and spirometry at 3 months following COVID-19. Of them, forty-six patients returned for follow-up assessments at 6 months.Findings At 2-3 months, 83% of patients had at least one cardiopulmonary symptom versus 33% of controls. Patients and controls had comparable biventricular volumes and function. Native cardiac T1 (marker of inflammation) and late gadolinium enhancement (LGE, marker of focal fibrosis) were increased in patients. Sixty percent of patients had lung parenchymal abnormalities on CMR and 55% had reduced peak oxygen consumption (pVO2) on CPET.By 6 months, 53% of patients remained symptomatic. On CMR, indexed right ventricular (RV) end-diastolic volume (−4·3 mls/m2, P=0·005) decreased and RV ejection fraction (+3·2%, P=0·0003) increased. Native T1 and LGE improved and was comparable to controls. Lung parenchymal abnormalities and peak VO2, although better, were abnormal in patients versus controls. 31% had reduced pVO2 secondary to fatigue and submaximal tests. Cardiopulmonary symptoms in patients did not associate with CMR, lung function, or CPET measures.Interpretation In patients, cardiopulmonary abnormalities improve over time, though some measures remain abnormal relative to controls. Persistent symptoms at 6 months post-COVID-19 did not associate with objective measures of cardiopulmonary health.Funding NIHR Oxford and Oxford Health BRC, Oxford BHF CRE, UKRI and Wellcome Trust.Competing Interest StatementMC reports a grant from the NIHR Oxford Biomedical Research Centre. EMT reports a grant from the NIHR Oxford Biomedical Research Centre and is a shareholder in Perspectum. AL is a shareholder in Perspectum. SKP has a US patent (6)1/387,591 licensed to Siemens and US patents 61/630,508 and 61-630,510 licensed to Perspectum. VMF reports grants from the British Heart Foundation and the National Institute Health Research Oxford Biomedical Research Centre. SN reports grants from the NIHR Oxford Biomedical Research Centre and UK Research and Innovation and is a shareholder in Perspectum. SN was a board member and consultant to Perspectum until 2019. SN has US patents 61/630,508 and 61-630,510 licensed to Perspectum. BR reports grants from the Oxford British Heart Foundation Centre for Research Excellence, the NIHR Oxford Biomedical Research Centre and the United Kingdom Research Innovation Award. All other authors do not have relationships with industry or funding sources to declare.Clinical TrialNCT04510025Funding StatementThe work was supported by the NIHR Oxford and Oxford Health Biomedical Research Centre, Oxford British Heart Foundation (BHF) Centre of Research Excellence, United Kingdom Research Innovation and Wellcome Trust. This project is part of a tier 3 study (C-MORE) within the collaborative research programme entitled PHOSP-COVID Post-hospitalization COVID-19 study: a national consortium to understand and improve long-term health outcomes. Funded by the Medical Research Council and Department of Health and Social Care/National Institute for Health Research Grant (MR/V027859/1) ISRCTN number 10980107.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved in the United Kingdom by the North West Preston Research Ethics Committee (reference 20/NW/0235).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article will be shared on reasonable request to the corresponding author, subject to institutional and ethical committee approvals.